Kamada (KMDA) secures FDA approval for its Houston plasma collection center

Rhea-AI Filing Summary

Kamada Ltd. reports that the U.S. Food and Drug Administration has approved its plasma collection center in Houston, Texas. This information is provided through a Form 6-K submission that incorporates the report by reference into several existing Form S-8 registration statements. The FDA approval of the Houston plasma collection center represents a regulatory milestone for Kamada’s plasma-related activities in the United States.

Positive

• FDA approval of Kamada Ltd.'s plasma collection center in Houston, Texas, representing a notable regulatory milestone for its plasma-related activities.

Negative

• None.

Insights

Biopharma regulatory analyst

FDA approval of Kamada's Houston plasma center is a positive regulatory milestone disclosed via Form 6-K.

Kamada Ltd. reports that the U.S. Food and Drug Administration approved its plasma collection center in Houston, Texas, as noted in an attached exhibit. This establishes that the facility has received the necessary FDA signoff referenced in the disclosure.

The event is important from a regulatory perspective because operation of a plasma collection center is tied to compliance with FDA requirements. Having this approval in place can be relevant to Kamada’s broader plasma-related business, even though no financial figures or volumes are described here.

The information is furnished on a Form 6-K and incorporated by reference into multiple Form S-8 registration statements, indicating the company is aligning its employee equity plans and related disclosures with this regulatory development.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the Month of August 2025

Commission File Number 001-35948

Kamada Ltd.

(Translation of registrant’s name into English)

2 Holzman Street
Science Park, P.O. Box 4081
Rehovot 7670402
Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

This Form 6-K is being incorporated by reference into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267 and 333-265866.

1

The following exhibit is attached:

99.1 Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 11, 2025	KAMADA LTD.
	By:	/s/ Nir Livneh
		Nir Livneh Vice President General Counsel and Corporate Secretary

3

EXHIBIT INDEX

EXHIBIT NO.		DESCRIPTION
99.1		Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas

4

FAQ

What key development did Kamada Ltd. (KMDA) report in this Form 6-K?

Kamada Ltd. reported that the U.S. Food and Drug Administration approved its plasma collection center in Houston, Texas, as described in Exhibit 99.1.

Where is Kamada Ltd.'s FDA-approved plasma collection center located?

The plasma collection center that received FDA approval is located in Houston, Texas.

How is this Form 6-K used in relation to Kamada Ltd.'s other SEC registrations?

This Form 6-K is being incorporated by reference into Kamada Ltd.'s existing Form S-8 registration statements with file numbers 333-192720, 333-207933, 333-215983, 333-222891, 333-233267 and 333-265866.

What exhibit accompanies Kamada Ltd.'s August 2025 Form 6-K?

The Form 6-K includes Exhibit 99.1, titled “Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas.”

What type of SEC filer is Kamada Ltd. in this report?

Kamada Ltd. submitted this report as a foreign private issuer on Form 6-K under the Securities Exchange Act of 1934.